60 Degrees Pharmaceuticals, Inc.

NasdaqCM SXTP

60 Degrees Pharmaceuticals, Inc. Market Capitalization on January 14, 2025: USD 2.14 M

60 Degrees Pharmaceuticals, Inc. Market Capitalization is USD 2.14 M on January 14, 2025, a 125.70% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • 60 Degrees Pharmaceuticals, Inc. 52-week high Market Capitalization is USD 5.08 M on December 11, 2024, which is 137.43% above the current Market Capitalization.
  • 60 Degrees Pharmaceuticals, Inc. 52-week low Market Capitalization is USD 89.60 K on August 07, 2024, which is -95.81% below the current Market Capitalization.
  • 60 Degrees Pharmaceuticals, Inc. average Market Capitalization for the last 52 weeks is USD 948.02 K.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
NasdaqCM: SXTP

60 Degrees Pharmaceuticals, Inc.

CEO Dr. Geoffrey Stuart Dow
IPO Date July 12, 2023
Location United States
Headquarters 1025 Connecticut Avenue NW
Employees 3
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

StockViz Staff

January 15, 2025

Any question? Send us an email